Combination phentermine and topiramate for weight maintenance: the first Australian experience.

[1]  F. Greenway,et al.  Addiction potential of phentermine prescribed during long-term treatment of obesity , 2014, International Journal of Obesity.

[2]  A. Trimmer,et al.  Inequalities in bariatric surgery in Australia: findings from 49 364 obese participants in a prospective cohort study , 2013, The Medical journal of Australia.

[3]  A. Shulkes,et al.  Ketosis and appetite-mediating nutrients and hormones after weight loss , 2013, European Journal of Clinical Nutrition.

[4]  F. Greenway,et al.  Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.

[5]  K. Gadde,et al.  Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.

[6]  A. Shulkes,et al.  Long-term persistence of hormonal adaptations to weight loss. , 2011, The New England journal of medicine.

[7]  K. Gadde,et al.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[8]  G. Bray,et al.  A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. , 2003, Obesity research.

[9]  A. Powell.  Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .